To include your compound in the COVID-19 Resource Center, submit it here.

Rome: tackling repeat DNA for cancer, autoimmunity

Rome launches with $50M series A round to leverage repeat biology

GV-incubated Rome joins a growing cadre of companies targeting repeat biology, with plans to suppress repeat DNA-induced innate immune responses to treat autoimmune disorders and activate the same pathways for cancer.

Rome Therapeutics Inc. launched Monday with a $50 million series A round co-led by GV and Arch Venture Partners; Partners Innovation Fund also participated.

The company is going after proteins or peptides encoded by repeat sequences including endogenous retroviruses (ERVs), long interspersed nuclear elements (LINEs) and

Read the full 769 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE